.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Citi
US Army
Healthtrust
Cipla
Chubb
Queensland Health
Accenture
Baxter
Novartis

Generated: July 23, 2017

DrugPatentWatch Database Preview

Netupitant; palonosetron hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for netupitant; palonosetron hydrochloride and what is the scope of netupitant; palonosetron hydrochloride patent protection?

Netupitant; palonosetron hydrochloride
is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Netupitant; palonosetron hydrochloride has one hundred and twenty-four patent family members in sixty-two countries.

There are four drug master file entries for netupitant; palonosetron hydrochloride. Two suppliers are listed for this compound.

Summary for Generic Name: netupitant; palonosetron hydrochloride

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list4
Suppliers / Packagers: see list2
Clinical Trials: see list2,319
Drug Prices:see low prices
DailyMed Link:netupitant; palonosetron hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes9,186,357► Subscribe ► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes8,623,826► Subscribe ► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes8,951,969► SubscribeY ► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes9,271,975► Subscribe ► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: netupitant; palonosetron hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 20145,202,333► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: netupitant; palonosetron hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,479,483 4-phenyl-pyridine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: netupitant; palonosetron hydrochloride

Country Document Number Estimated Expiration
Cuba24048► Subscribe
United Kingdom0003908► Subscribe
Denmark2722045► Subscribe
Singapore91856► Subscribe
TunisiaSN00032► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NETUPITANT; PALONOSETRON HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00044Denmark► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
90040-0Sweden► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2015036Lithuania► SubscribePRODUCT NAME: NETUPITANTUM; REGISTRATION NO/DATE: EU/1/15/1001 20150527
745Luxembourg► SubscribePRODUCT NAME: NETUPITANT/PALONOSETRON ET LEURS DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (AKYNZEO); FIRST REGISTRATION: 20150527
1035115/01Switzerland► SubscribePRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Medtronic
Colorcon
Farmers Insurance
Accenture
Argus Health
UBS
Healthtrust
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot